de la Taille A, Hayek O R, Buttyan R, Bagiella E, Burchardt M, Katz A E
The Squier Urological Clinic, Columbia University College of Physicians and Surgeons, Department of Urology, Columbia-Presbyterian Medical Center, New York, NY 10032, USA.
BJU Int. 1999 Nov;84(7):845-50. doi: 10.1046/j.1464-410x.1999.00285.x.
To evaluate the in vitro activity of PC-SPES, a complex phytotherapeutic agent, against prostate cancer cell lines, and to assess its activity in suppressing serum prostate specific antigen (PSA) level in patients with prostate cancer.
Four variant prostate cancer cell lines (LNCaP and an apoptosis-resistant derivative, LNCaP-bcl-2, PC3 and DU145) were exposed to three different concentrations of PC-SPES extract. Cell viability was measured at 3, 4 and 5 days of exposure using a colorimetric assay and was compared with control cultures receiving aliquots of the ethanolic extraction medium alone. Clinically, a prospective study was initiated in patients with prostate cancer who refused conventional therapy or who had failed previous cryosurgery, radiation therapy and/or hormonal therapy. The patients were treated with PC-SPES (three capsules of 320 mg/day). The serum PSA responses and side-effects were evaluated.
All cultured prostate cancer cell lines showed a significant dose-dependent reduction in cellular viability (compared with control cultures) by exposure to 4 and 6 microL of PC-SPES extract/mL of culture medium (P<0.001). In contrast to the hormone-insensitive cell lines tested (LNCaP-bcl-2, PC-3 and DU-145), only the hormone-sensitive cell line LNCaP was affected by the lowest dose of PC-SPES extract tested (2 microL/mL medium). In the prospective clinical trial of 33 patients, with a mean (range) follow-up of 6.8 (2-24) months after initiating PC-SPES therapy, serum PSA levels were lower in 87% at 2 months and in 78% at 6 months (n=18, P=0.026). The side-effects in these patients were nipple tenderness in two (6%) and leg clots requiring heparinization in two (6%). No gynaecomastia or hot flashes were observed in this group and the treatment was well tolerated.
In this preliminary study, an extract of the phytotherapeutic agent PC-SPES was active in suppressing the growth of cultured hormone-sensitive and -insensitive prostate cancer cell lines. In the small clinical study, PC-SPES therapy decreased serum PSA levels in most patients. However, a longer follow-up and more patients will be required to evaluate the long-term efficacy of this new phytotherapy.
评估复合植物治疗剂PC - SPES对前列腺癌细胞系的体外活性，并评估其在抑制前列腺癌患者血清前列腺特异性抗原（PSA）水平方面的活性。
将四种变异的前列腺癌细胞系（LNCaP及其抗凋亡衍生物LNCaP - bcl - 2、PC3和DU145）暴露于三种不同浓度的PC - SPES提取物中。使用比色法在暴露3、4和5天时测量细胞活力，并与仅接受乙醇提取介质等分试样的对照培养物进行比较。临床上，对拒绝传统治疗或先前冷冻手术、放射治疗和/或激素治疗失败的前列腺癌患者开展了一项前瞻性研究。患者接受PC - SPES治疗（每日3粒，每粒320毫克）。评估血清PSA反应和副作用。
所有培养的前列腺癌细胞系在暴露于每毫升培养基4和6微升PC - SPES提取物时，细胞活力均呈现显著的剂量依赖性降低（与对照培养物相比，P<0.001）。与所测试的激素不敏感细胞系（LNCaP - bcl - 2、PC - 3和DU - 145）不同，仅激素敏感细胞系LNCaP受到所测试的最低剂量PC - SPES提取物（2微升/毫升培养基）的影响。在对33例患者的前瞻性临床试验中，开始PC - SPES治疗后平均（范围）随访6.8（2 - 24）个月，2个月时87%的患者血清PSA水平降低，6个月时78%的患者血清PSA水平降低（n = 18，P = 0.026）。这些患者的副作用为2例（6%）出现乳头触痛，2例（6%）出现需要肝素化治疗的腿部血栓。该组未观察到男性乳房发育或潮热，且治疗耐受性良好。
在这项初步研究中，植物治疗剂PC - SPES的提取物在抑制培养的激素敏感和激素不敏感前列腺癌细胞系生长方面具有活性。在小型临床研究中，PC - SPES治疗使大多数患者的血清PSA水平降低。然而，需要更长时间的随访和更多患者来评估这种新植物疗法的长期疗效。
